Contact
searchSearch
HMP Global
Login

Head & Neck Cancer Specialty Channel

Head & Neck Cancer
Specialty Channel
News
Sequential Chemoradiotherapy Plus Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
08/19/2025
Stephanie Holland
According to results from a phase 3 trial, sequential chemoradiotherapy plus concurrent chemoradiotherapy was noninferior compared to induction chemoradiotherapy plus concurrent chemoradiotherapy among newly diagnosed patients with...
According to results from a phase 3 trial, sequential chemoradiotherapy plus concurrent chemoradiotherapy was noninferior compared to induction chemoradiotherapy plus concurrent chemoradiotherapy among newly diagnosed patients with...
According to results from a...
08/19/2025
Oncology
Danny Rischin, MD, Peter MacCallum Cancer Centre
Videos
Adjuvant Cemiplimab as New Standard of Care for Patients With High-Risk Cutaneous Squamous Cell Carcinoma
06/06/2025
Danny Rischin, MD
Danny Rischin, MD, discusses the results from the phase 3 C-POST trial evaluating adjuvant cemiplimab for patients with high-risk cutaneous squamous cell carcinoma.
Danny Rischin, MD, discusses the results from the phase 3 C-POST trial evaluating adjuvant cemiplimab for patients with high-risk cutaneous squamous cell carcinoma.
Danny Rischin, MD, discusses the...
06/06/2025
Oncology
Conference Coverage
Adjuvant Nivolumab Plus Chemoradiotherapy Decreases Chance of Recurrence in Patients With Head and Neck Cancer
06/01/2025
Emily Estrada
The addition of nivolumab to cisplatin-based chemoradiotherapy after surgery improved disease-free survival for patients with locoregionally advanced squamous cell carcinoma of the head and neck, according to findings from the NIVOPOSTOP...
The addition of nivolumab to cisplatin-based chemoradiotherapy after surgery improved disease-free survival for patients with locoregionally advanced squamous cell carcinoma of the head and neck, according to findings from the NIVOPOSTOP...
The addition of nivolumab to...
06/01/2025
Oncology
News
Neoadjuvant Nivolumab Plus Chemotherapy and Chemoradiation for Patients With HPV-Negative Locally Advanced Head and Neck Squamous Cell Carcinoma
05/27/2025
Stephanie Holland
According to results from the phase 2 DEPEND trial, neoadjuvant nivolumab plus chemotherapy and response-stratified de-escalated chemoradiation demonstrated promise among patients with HPV-negative locally advanced head and neck squamous cell...
According to results from the phase 2 DEPEND trial, neoadjuvant nivolumab plus chemotherapy and response-stratified de-escalated chemoradiation demonstrated promise among patients with HPV-negative locally advanced head and neck squamous cell...
According to results from the...
05/27/2025
Oncology
News
First-Line Pembrolizumab With or Without Chemotherapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
04/08/2025
Stephanie Holland
According to long-term follow up results from the phase 3 KEYNOTE-048 study, first-line pembrolizumab with or without chemotherapy demonstrated long-term survival benefit among patients with recurrent or metastatic head and neck squamous cell...
According to long-term follow up results from the phase 3 KEYNOTE-048 study, first-line pembrolizumab with or without chemotherapy demonstrated long-term survival benefit among patients with recurrent or metastatic head and neck squamous cell...
According to long-term follow up...
04/08/2025
Oncology
News
Novel Engineered Toxin Body Targeting CTLA-4 Shows Potential Among Select Advanced Solid Tumors
03/06/2025
Allison Casey
According to a phase 1 trial, MT-8421, a novel ETB targeting CTLA4, demonstrated acceptable safety with no dose-limited toxicities among patients with select advanced solid tumors.
According to a phase 1 trial, MT-8421, a novel ETB targeting CTLA4, demonstrated acceptable safety with no dose-limited toxicities among patients with select advanced solid tumors.
According to a phase 1 trial,...
03/06/2025
Oncology
News
Promising Efficacy With Bevacizumab Plus Pembrolizumab for Platinum-Resistant Nasopharyngeal Carcinoma
01/23/2025
Stephanie Holland
Results from a phase 2 study found that the addition of bevacizumab to pembrolizumab had superior efficacy to pembrolizumab alone among patients with platinum-resistant recurrent or metastatic nasopharyngeal carcinoma.
Results from a phase 2 study found that the addition of bevacizumab to pembrolizumab had superior efficacy to pembrolizumab alone among patients with platinum-resistant recurrent or metastatic nasopharyngeal carcinoma.
Results from a phase 2 study...
01/23/2025
Oncology
News
First-Line Pembrolizumab Plus Chemotherapy Showed Promise Among Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
07/26/2024
Stephanie Holland
According to results from the KEYNOTE-B10 trial, first-line pembrolizumab plus carboplatin and paclitaxel showed promising antitumor activity with manageable safety among patients with recurrent or metastatic head and neck squamous cell...
According to results from the KEYNOTE-B10 trial, first-line pembrolizumab plus carboplatin and paclitaxel showed promising antitumor activity with manageable safety among patients with recurrent or metastatic head and neck squamous cell...
According to results from the...
07/26/2024
Oncology
Conference Coverage
Addition of Nivolumab to Triple Metronomic Chemotherapy Significantly Improved Overall Survival Among Patients With Advanced Head and Neck Squamous Cell Carcinoma
06/20/2024

Stephanie Holland 

Stephanie Holland 
The addition of low-dose nivolumab to triple metronomic chemotherapy significantly improved overall survival among patients with relapsed, recurrent, or newly diagnosed advanced head and neck squamous cell carcinoma.
The addition of low-dose nivolumab to triple metronomic chemotherapy significantly improved overall survival among patients with relapsed, recurrent, or newly diagnosed advanced head and neck squamous cell carcinoma.
The addition of low-dose...
06/20/2024
Oncology
News
FDA Grants Accelerated Approval to Repotrectinib for Adult and Pediatric Patients With NRTK Gene Fusion-Positive Solid Tumors
06/14/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the phase 1/2 TRIDENT-1 study, the US FDA has granted accelerated approval to repotrectinib for adult and pediatric patients 12 years and older with NRTK gene fusion-positive solid tumors.
Based on results from the phase 1/2 TRIDENT-1 study, the US FDA has granted accelerated approval to repotrectinib for adult and pediatric patients 12 years and older with NRTK gene fusion-positive solid tumors.
Based on results from the phase...
06/14/2024
Oncology
Conference Coverage
Tisotumab Vedotin Showed Promising Clinical Activity Among Heavily Pretreated Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
06/11/2024

Stephanie Holland 

Stephanie Holland 
According to updated results from the phase 2 innovaTV 207 trial, tisotumab vedotin showed promising clinical activity among patients with heavily pretreated recurrent or metastatic head and neck squamous cell carcinoma.
According to updated results from the phase 2 innovaTV 207 trial, tisotumab vedotin showed promising clinical activity among patients with heavily pretreated recurrent or metastatic head and neck squamous cell carcinoma.
According to updated results...
06/11/2024
Oncology

News

News
Sequential Chemoradiotherapy Plus Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
08/19/2025
Stephanie Holland
According to results from a phase 3 trial, sequential chemoradiotherapy plus concurrent chemoradiotherapy was noninferior compared to induction chemoradiotherapy plus concurrent chemoradiotherapy among newly diagnosed patients with...
According to results from a phase 3 trial, sequential chemoradiotherapy plus concurrent chemoradiotherapy was noninferior compared to induction chemoradiotherapy plus concurrent chemoradiotherapy among newly diagnosed patients with...
According to results from a...
08/19/2025
Oncology
Danny Rischin, MD, Peter MacCallum Cancer Centre
Videos
Adjuvant Cemiplimab as New Standard of Care for Patients With High-Risk Cutaneous Squamous Cell Carcinoma
06/06/2025
Danny Rischin, MD
Danny Rischin, MD, discusses the results from the phase 3 C-POST trial evaluating adjuvant cemiplimab for patients with high-risk cutaneous squamous cell carcinoma.
Danny Rischin, MD, discusses the results from the phase 3 C-POST trial evaluating adjuvant cemiplimab for patients with high-risk cutaneous squamous cell carcinoma.
Danny Rischin, MD, discusses the...
06/06/2025
Oncology
Conference Coverage
Adjuvant Nivolumab Plus Chemoradiotherapy Decreases Chance of Recurrence in Patients With Head and Neck Cancer
06/01/2025
Emily Estrada
The addition of nivolumab to cisplatin-based chemoradiotherapy after surgery improved disease-free survival for patients with locoregionally advanced squamous cell carcinoma of the head and neck, according to findings from the NIVOPOSTOP...
The addition of nivolumab to cisplatin-based chemoradiotherapy after surgery improved disease-free survival for patients with locoregionally advanced squamous cell carcinoma of the head and neck, according to findings from the NIVOPOSTOP...
The addition of nivolumab to...
06/01/2025
Oncology
News
Neoadjuvant Nivolumab Plus Chemotherapy and Chemoradiation for Patients With HPV-Negative Locally Advanced Head and Neck Squamous Cell Carcinoma
05/27/2025
Stephanie Holland
According to results from the phase 2 DEPEND trial, neoadjuvant nivolumab plus chemotherapy and response-stratified de-escalated chemoradiation demonstrated promise among patients with HPV-negative locally advanced head and neck squamous cell...
According to results from the phase 2 DEPEND trial, neoadjuvant nivolumab plus chemotherapy and response-stratified de-escalated chemoradiation demonstrated promise among patients with HPV-negative locally advanced head and neck squamous cell...
According to results from the...
05/27/2025
Oncology
News
First-Line Pembrolizumab With or Without Chemotherapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
04/08/2025
Stephanie Holland
According to long-term follow up results from the phase 3 KEYNOTE-048 study, first-line pembrolizumab with or without chemotherapy demonstrated long-term survival benefit among patients with recurrent or metastatic head and neck squamous cell...
According to long-term follow up results from the phase 3 KEYNOTE-048 study, first-line pembrolizumab with or without chemotherapy demonstrated long-term survival benefit among patients with recurrent or metastatic head and neck squamous cell...
According to long-term follow up...
04/08/2025
Oncology
News
Novel Engineered Toxin Body Targeting CTLA-4 Shows Potential Among Select Advanced Solid Tumors
03/06/2025
Allison Casey
According to a phase 1 trial, MT-8421, a novel ETB targeting CTLA4, demonstrated acceptable safety with no dose-limited toxicities among patients with select advanced solid tumors.
According to a phase 1 trial, MT-8421, a novel ETB targeting CTLA4, demonstrated acceptable safety with no dose-limited toxicities among patients with select advanced solid tumors.
According to a phase 1 trial,...
03/06/2025
Oncology
News
Promising Efficacy With Bevacizumab Plus Pembrolizumab for Platinum-Resistant Nasopharyngeal Carcinoma
01/23/2025
Stephanie Holland
Results from a phase 2 study found that the addition of bevacizumab to pembrolizumab had superior efficacy to pembrolizumab alone among patients with platinum-resistant recurrent or metastatic nasopharyngeal carcinoma.
Results from a phase 2 study found that the addition of bevacizumab to pembrolizumab had superior efficacy to pembrolizumab alone among patients with platinum-resistant recurrent or metastatic nasopharyngeal carcinoma.
Results from a phase 2 study...
01/23/2025
Oncology
News
First-Line Pembrolizumab Plus Chemotherapy Showed Promise Among Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
07/26/2024
Stephanie Holland
According to results from the KEYNOTE-B10 trial, first-line pembrolizumab plus carboplatin and paclitaxel showed promising antitumor activity with manageable safety among patients with recurrent or metastatic head and neck squamous cell...
According to results from the KEYNOTE-B10 trial, first-line pembrolizumab plus carboplatin and paclitaxel showed promising antitumor activity with manageable safety among patients with recurrent or metastatic head and neck squamous cell...
According to results from the...
07/26/2024
Oncology
Conference Coverage
Addition of Nivolumab to Triple Metronomic Chemotherapy Significantly Improved Overall Survival Among Patients With Advanced Head and Neck Squamous Cell Carcinoma
06/20/2024

Stephanie Holland 

Stephanie Holland 
The addition of low-dose nivolumab to triple metronomic chemotherapy significantly improved overall survival among patients with relapsed, recurrent, or newly diagnosed advanced head and neck squamous cell carcinoma.
The addition of low-dose nivolumab to triple metronomic chemotherapy significantly improved overall survival among patients with relapsed, recurrent, or newly diagnosed advanced head and neck squamous cell carcinoma.
The addition of low-dose...
06/20/2024
Oncology
News
FDA Grants Accelerated Approval to Repotrectinib for Adult and Pediatric Patients With NRTK Gene Fusion-Positive Solid Tumors
06/14/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the phase 1/2 TRIDENT-1 study, the US FDA has granted accelerated approval to repotrectinib for adult and pediatric patients 12 years and older with NRTK gene fusion-positive solid tumors.
Based on results from the phase 1/2 TRIDENT-1 study, the US FDA has granted accelerated approval to repotrectinib for adult and pediatric patients 12 years and older with NRTK gene fusion-positive solid tumors.
Based on results from the phase...
06/14/2024
Oncology

Interactive Features

Quiz
Quiz: Docetaxel Plus Radiotherapy For Cisplatin-Ineligible Patients With Head and Neck Carcinoma
09/02/2022
In a study evaluating the addition of docetaxel to radiotherapy for head and neck squamous cell carcinoma, which outcome was improved with docetaxel compared to radiation alone? Test your knowledge with our quiz.
In a study evaluating the addition of docetaxel to radiotherapy for head and neck squamous cell carcinoma, which outcome was improved with docetaxel compared to radiation alone? Test your knowledge with our quiz.
In a study evaluating the...
09/02/2022
Oncology
Test Your Knowledge
Quiz: Single Agent Vs Combo Therapy for Cetuximab in CRC, Head and Neck Cancer
04/22/2021
True or False: Cetuximab, a novel dosing regimen recently approved by the FDA, can be dosed alone or in combination with chemotherapy for patients with either colorectal or head and neck cancer.
True or False: Cetuximab, a novel dosing regimen recently approved by the FDA, can be dosed alone or in combination with chemotherapy for patients with either colorectal or head and neck cancer.
True or False: Cetuximab, a...
04/22/2021
Oncology
Test Your Knowledge
Quiz: Is Lenvatinib a Second-Line Treatment Option for Patients with Thymic Carcinoma?
07/30/2020
True or False: Recent findings suggest that lenvatinib is a potential treatment option for patients with previously treated advanced or metastatic thymic carcinoma.
True or False: Recent findings suggest that lenvatinib is a potential treatment option for patients with previously treated advanced or metastatic thymic carcinoma.
True or False: Recent findings...
07/30/2020
Oncology
Test Your Knowledge
Quiz: Is Age Tied to Disease Progression in Adults With Papillary Thyroid Cancer?
07/13/2020
07/13/2020
Oncology
Test Your Knowledge
Quiz: Late-Line Bemarituzumab Therapy for Advanced Gastroesophageal Cancer
05/22/2020
True or False: Late-line bemarituzumab has been shown to be active and well-tolerated in patients with advanced FGFR2b-overexpressing gastric and GEA.
True or False: Late-line bemarituzumab has been shown to be active and well-tolerated in patients with advanced FGFR2b-overexpressing gastric and GEA.
True or False: Late-line...
05/22/2020
Oncology
Test Your Knowledge
Quiz: Can Acupuncture Prevent Xerostomia in Head and Neck Cancer?
03/02/2020
True or False: Acupuncture may prevent radiation-induced xerostomia in patients with head and neck cancer.
True or False: Acupuncture may prevent radiation-induced xerostomia in patients with head and neck cancer.
True or False: Acupuncture may...
03/02/2020
Oncology
Test Your Knowledge
Quiz: Adding Which Drug to This Combo Therapy Improves Nasopharyngeal Carcinoma Outcomes?
11/08/2019
Adding which drug to cisplatin and chemoradiotherapy improved survival in patients with nasopharyngeal carcinoma?
Adding which drug to cisplatin and chemoradiotherapy improved survival in patients with nasopharyngeal carcinoma?
Adding which drug to cisplatin...
11/08/2019
Oncology
Test Your Knowledge
Quiz: Temozolomide Combo for MGMT-Methylated Glioblastoma
10/01/2019
Which drug plus temozolomide is clinically beneficial for newly diagnosed MGMT-methylated glioblastoma?
Which drug plus temozolomide is clinically beneficial for newly diagnosed MGMT-methylated glioblastoma?
Which drug plus temozolomide is...
10/01/2019
Oncology
Test Your Knowledge
Quiz: Palbociclib and Cetuximab as Therapy for HPV-Unrelated HNSCC
08/29/2019
True or False: Palbociclib and cetuximab therapy has shown promising activity in patients with HPV-unrelated, platinum- or cetuximab-resistant, head and neck squamous-cell carcinomas.
True or False: Palbociclib and cetuximab therapy has shown promising activity in patients with HPV-unrelated, platinum- or cetuximab-resistant, head and neck squamous-cell carcinomas.
True or False: Palbociclib and...
08/29/2019
Oncology
Test Your Knowledge
Quiz: Risk for Brain Metastases Higher With Twice-Daily Radiotherapy for SCLC?
08/01/2019
True or false: Patients with SCLC undergoing radiotherapy twice daily are more likely to have brain metastases after prophylactic cranial irradiation than those given radiotherapy once daily.
True or false: Patients with SCLC undergoing radiotherapy twice daily are more likely to have brain metastases after prophylactic cranial irradiation than those given radiotherapy once daily.
True or false: Patients with...
08/01/2019
Oncology

Recent News

News
Sequential Chemoradiotherapy Plus Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
08/19/2025
Stephanie Holland
According to results from a phase 3 trial, sequential chemoradiotherapy plus concurrent chemoradiotherapy was noninferior compared to induction chemoradiotherapy plus concurrent chemoradiotherapy among newly diagnosed patients with...
According to results from a phase 3 trial, sequential chemoradiotherapy plus concurrent chemoradiotherapy was noninferior compared to induction chemoradiotherapy plus concurrent chemoradiotherapy among newly diagnosed patients with...
According to results from a...
08/19/2025
Oncology
Conference Coverage
Adjuvant Nivolumab Plus Chemoradiotherapy Decreases Chance of Recurrence in Patients With Head and Neck Cancer
06/01/2025
Emily Estrada
The addition of nivolumab to cisplatin-based chemoradiotherapy after surgery improved disease-free survival for patients with locoregionally advanced squamous cell carcinoma of the head and neck, according to findings from the NIVOPOSTOP...
The addition of nivolumab to cisplatin-based chemoradiotherapy after surgery improved disease-free survival for patients with locoregionally advanced squamous cell carcinoma of the head and neck, according to findings from the NIVOPOSTOP...
The addition of nivolumab to...
06/01/2025
Oncology
News
Neoadjuvant Nivolumab Plus Chemotherapy and Chemoradiation for Patients With HPV-Negative Locally Advanced Head and Neck Squamous Cell Carcinoma
05/27/2025
Stephanie Holland
According to results from the phase 2 DEPEND trial, neoadjuvant nivolumab plus chemotherapy and response-stratified de-escalated chemoradiation demonstrated promise among patients with HPV-negative locally advanced head and neck squamous cell...
According to results from the phase 2 DEPEND trial, neoadjuvant nivolumab plus chemotherapy and response-stratified de-escalated chemoradiation demonstrated promise among patients with HPV-negative locally advanced head and neck squamous cell...
According to results from the...
05/27/2025
Oncology
News
First-Line Pembrolizumab With or Without Chemotherapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
04/08/2025
Stephanie Holland
According to long-term follow up results from the phase 3 KEYNOTE-048 study, first-line pembrolizumab with or without chemotherapy demonstrated long-term survival benefit among patients with recurrent or metastatic head and neck squamous cell...
According to long-term follow up results from the phase 3 KEYNOTE-048 study, first-line pembrolizumab with or without chemotherapy demonstrated long-term survival benefit among patients with recurrent or metastatic head and neck squamous cell...
According to long-term follow up...
04/08/2025
Oncology
News
Novel Engineered Toxin Body Targeting CTLA-4 Shows Potential Among Select Advanced Solid Tumors
03/06/2025
Allison Casey
According to a phase 1 trial, MT-8421, a novel ETB targeting CTLA4, demonstrated acceptable safety with no dose-limited toxicities among patients with select advanced solid tumors.
According to a phase 1 trial, MT-8421, a novel ETB targeting CTLA4, demonstrated acceptable safety with no dose-limited toxicities among patients with select advanced solid tumors.
According to a phase 1 trial,...
03/06/2025
Oncology
News
Promising Efficacy With Bevacizumab Plus Pembrolizumab for Platinum-Resistant Nasopharyngeal Carcinoma
01/23/2025
Stephanie Holland
Results from a phase 2 study found that the addition of bevacizumab to pembrolizumab had superior efficacy to pembrolizumab alone among patients with platinum-resistant recurrent or metastatic nasopharyngeal carcinoma.
Results from a phase 2 study found that the addition of bevacizumab to pembrolizumab had superior efficacy to pembrolizumab alone among patients with platinum-resistant recurrent or metastatic nasopharyngeal carcinoma.
Results from a phase 2 study...
01/23/2025
Oncology
News
First-Line Pembrolizumab Plus Chemotherapy Showed Promise Among Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
07/26/2024
Stephanie Holland
According to results from the KEYNOTE-B10 trial, first-line pembrolizumab plus carboplatin and paclitaxel showed promising antitumor activity with manageable safety among patients with recurrent or metastatic head and neck squamous cell...
According to results from the KEYNOTE-B10 trial, first-line pembrolizumab plus carboplatin and paclitaxel showed promising antitumor activity with manageable safety among patients with recurrent or metastatic head and neck squamous cell...
According to results from the...
07/26/2024
Oncology
Conference Coverage
Addition of Nivolumab to Triple Metronomic Chemotherapy Significantly Improved Overall Survival Among Patients With Advanced Head and Neck Squamous Cell Carcinoma
06/20/2024

Stephanie Holland 

Stephanie Holland 
The addition of low-dose nivolumab to triple metronomic chemotherapy significantly improved overall survival among patients with relapsed, recurrent, or newly diagnosed advanced head and neck squamous cell carcinoma.
The addition of low-dose nivolumab to triple metronomic chemotherapy significantly improved overall survival among patients with relapsed, recurrent, or newly diagnosed advanced head and neck squamous cell carcinoma.
The addition of low-dose...
06/20/2024
Oncology
News
FDA Grants Accelerated Approval to Repotrectinib for Adult and Pediatric Patients With NRTK Gene Fusion-Positive Solid Tumors
06/14/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the phase 1/2 TRIDENT-1 study, the US FDA has granted accelerated approval to repotrectinib for adult and pediatric patients 12 years and older with NRTK gene fusion-positive solid tumors.
Based on results from the phase 1/2 TRIDENT-1 study, the US FDA has granted accelerated approval to repotrectinib for adult and pediatric patients 12 years and older with NRTK gene fusion-positive solid tumors.
Based on results from the phase...
06/14/2024
Oncology
Conference Coverage
Tisotumab Vedotin Showed Promising Clinical Activity Among Heavily Pretreated Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
06/11/2024

Stephanie Holland 

Stephanie Holland 
According to updated results from the phase 2 innovaTV 207 trial, tisotumab vedotin showed promising clinical activity among patients with heavily pretreated recurrent or metastatic head and neck squamous cell carcinoma.
According to updated results from the phase 2 innovaTV 207 trial, tisotumab vedotin showed promising clinical activity among patients with heavily pretreated recurrent or metastatic head and neck squamous cell carcinoma.
According to updated results...
06/11/2024
Oncology
News
Genotype-Guided Therapy Demonstrates High Response and Survival Rates for Patients With R/R DLBCL
09/26/2025
Emily Estrada
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE...
09/26/2025
Oncology
News
PD-1/PD-L1 Inhibitor Monotherapy Demonstrates Accceptable Safety, Limited Efficacy for R/R DLBCL
09/26/2025
Emily Estrada
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Treatment of R/R diffuse large...
09/26/2025
Oncology
News
Polatuzumab-Based Regimens Demonstrate Promising Efficacy for R/R DLBCL Compared to Traditional Salvage Therapies
09/26/2025
Emily Estrada
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Compared with traditional...
09/26/2025
Oncology
FDA Approval
FDA Approves Imlunestrant for Patients With ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer
09/25/2025
Stephanie Holland
The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.
The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.
The FDA has approved...
09/25/2025
Oncology
News
Pexidartinib Shows Durable Response Among Patients with Tenosynovial Giant Cell Tumors
09/25/2025
Allison Casey
Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.
Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.
Pexidartinib showed sustained...
09/25/2025
Oncology
News
Clarithromycin-Based Quadruplet Therapy Demonstrates Promising Clinical Responses for Treatment of Relapsed/Refractory Multiple Myeloma
09/24/2025
Emily Estrada
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with...
09/24/2025
Oncology
News
First-Line mFOLFIRINOX, S-IROX Fail to Improve Survival Among Patients With Recurrent or Metastatic Pancreatic Cancer
09/23/2025
Stephanie Holland
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3...
09/23/2025
Oncology
News
Novel Anti-CSF1 Receptor Antibody for Patients With Tenosynovial Giant Cell Tumor
09/23/2025
Allison Casey
According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.
According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.
According to a phase 2a trial,...
09/23/2025
Oncology
News
Adverse Events With Pexidartinib for Patients With Tenosynovial Giant Cell Tumor
09/23/2025
Allison Casey
According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.
According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.
According to an analysis of the...
09/23/2025
Oncology
News
Trifluridine/Tipiracil Plus Bevacizumab Escalation Demonstrates Promise Among Patients With Advanced or Unresectable Metastatic Colorectal Cancer
09/22/2025
Stephanie Holland
According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...
According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...
According to results from the...
09/22/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use